Alembic Pharmaceuticals Ltd Stock Price Today (NSE: APLLTD)
Fundamental Score
Alembic Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Alembic Pharmaceuticals Ltd share price today is ₹777.00, up +0.00% on NSE/BSE as of 17 February 2026. Alembic Pharmaceuticals Ltd (APLLTD) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹17.84K (Cr). The 52-week high for APLLTD share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 28.12x, APLLTD is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.38% and a debt-to-equity ratio of 0.28.
Alembic Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Alembic Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Alembic Pharmaceuticals Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while vital for societal well-being, presents a complex landscape for value investors. Regulatory hurdles, patent cliffs, and evolving healthcare landscapes necessitate meticulous due diligence. This analysis delves into the financial health of Alembic Pharmaceuticals, focusing on capital safety and sustainable value. Currently, the Alembic Pharmaceuticals share price stands at ₹797.65. We will assess key metrics to understand its investment viability from a conservative, long-term perspective. This is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Alembic Pharmaceuticals' Price-to-Earnings (PE) ratio of 28.12 warrants careful consideration. Relative to the broader market, this suggests a premium valuation, implying higher growth expectations. However, a conservative approach demands understanding the sustainability of these expectations. When comparing Alembic Pharmaceuticals Ltd with peers like
Mankind Pharma Ltd, assessing management quality becomes crucial. Are Alembic's strategic decisions and capital allocation as effective as those of Mankind Pharma Ltd? This comparison influences long-term projections.Return on Capital Employed (ROCE) is a critical indicator of a company's ability to generate profits from its invested capital. Alembic Pharmaceuticals' ROCE of 13.05% is adequate, but not exceptional. This figure directly impacts the company's economic moat. A higher ROCE, consistently maintained, suggests a stronger ability to fend off competition and maintain profitability. A lower ROCE, like the current 13.05%, indicates a potentially weaker competitive advantage. We need to see if this ROCE can consistently stay above their cost of capital, this consistency leads to sustainable value creation in the long run, creating wealth for its shareholders.
Further investigation into Alembic Pharmaceuticals' debt levels, cash flow generation, and pipeline of new products is essential. These factors, combined with a thorough understanding of its competitive landscape and regulatory risks, will contribute to a more informed assessment of its long-term value and suitability for a risk-averse, value-oriented portfolio.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alembic Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of APLLTD across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (17.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (28.80%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (15.91%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (9.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1236.03 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (-8.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-7.96% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Alembic Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Alembic Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About APLLTD (Alembic Pharmaceuticals Ltd)
Alembic Pharmaceuticals Ltd (APLLTD) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹17.84K (Cr). Alembic Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 11.38% and a ROCE of 13.05%. The debt-to-equity ratio stands at 0.28, reflecting the company's capital structure. Investors tracking APLLTD share price can monitor key metrics including P/E ratio, promoter holding of 69.74%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
APLLTD Share Price: Frequently Asked Questions
What is the current share price of Alembic Pharmaceuticals Ltd (APLLTD)?
As of 17 Feb 2026, 10:07 am IST, Alembic Pharmaceuticals Ltd share price is ₹777.00. The APLLTD stock has a market capitalisation of ₹17.84K (Cr) on NSE/BSE.
Is APLLTD share price Overvalued or Undervalued?
APLLTD share price is currently trading at a P/E ratio of 28.12x, compared to the industry average of 31.77x. Based on this relative valuation, the Alembic Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of APLLTD share price?
The 52-week high of APLLTD share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Alembic Pharmaceuticals Ltd share price?
Key factors influencing APLLTD share price include quarterly earnings growth (Sales Growth: 15.91%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alembic Pharmaceuticals Ltd a good stock for long-term investment?
Alembic Pharmaceuticals Ltd shows a 5-year Profit Growth of -7.96% and an ROE of 11.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.28 before investing in APLLTD shares.
How does Alembic Pharmaceuticals Ltd compare with its industry peers?
Alembic Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare APLLTD share price P/E of 28.12x and ROE of 11.38% against the industry averages to determine competitive standing.
What is the P/E ratio of APLLTD and what does it mean?
APLLTD share price has a P/E ratio of 28.12x compared to the industry average of 31.77x. Investors pay ₹28 for every ₹1 of annual earnings.
How is APLLTD performing according to Bull Run's analysis?
APLLTD has a Bull Run fundamental score of 51/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does APLLTD belong to?
APLLTD operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alembic Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for APLLTD?
APLLTD has an ROE of 11.38%, which shows decent profitability but room for improvement. ROE measures how efficiently Alembic Pharmaceuticals Ltd generates profits from shareholders capital.
How is APLLTD debt-to-equity ratio and what does it indicate?
APLLTD has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk.
What is APLLTD dividend yield and is it a good dividend stock?
APLLTD offers a dividend yield of 1.21%, meaning you receive ₹1.21 annual dividend for every ₹100 invested in Alembic Pharmaceuticals Ltd shares.
How has APLLTD share price grown over the past 5 years?
APLLTD has achieved 5-year growth rates of: Sales Growth 7.69%, Profit Growth -7.96%, and EPS Growth -8.73%.
What is the promoter holding in APLLTD and why does it matter?
Promoters hold 69.74% of APLLTD shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Alembic Pharmaceuticals Ltd.
What is APLLTD market capitalisation category?
APLLTD has a market capitalisation of ₹17841 crores, placing it in the Mid-cap category.
How volatile is APLLTD stock?
APLLTD has a beta of N/A. A beta > 1 suggests the Alembic Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is APLLTD operating profit margin trend?
APLLTD has a 5-year average Operating Profit Margin (OPM) of 17.01%, indicating the company's operational efficiency.
How is APLLTD quarterly performance?
Recent quarterly performance shows Alembic Pharmaceuticals Ltd YoY Sales Growth of 15.91% and YoY Profit Growth of 28.80%.
What is the institutional holding pattern in APLLTD?
APLLTD has FII holding of 4.04% and DII holding of 16.30%. Significant institutional holding often suggests professional confidence in the Alembic Pharmaceuticals Ltd stock.